SMMT * logo

Summit Therapeutics BMV:SMMT * Stock Report

Last Price

Mex$374.00

Market Cap

Mex$308.5b

7D

0%

1Y

n/a

Updated

08 Nov, 2024

Data

Company Financials +

Summit Therapeutics Inc.

BMV:SMMT * Stock Report

Market Cap: Mex$308.5b

SMMT * Stock Overview

A biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom.

SMMT * fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Summit Therapeutics Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Summit Therapeutics
Historical stock prices
Current Share PriceUS$374.00
52 Week HighUS$430.00
52 Week LowUS$258.50
Beta-0.92
11 Month Change-0.53%
3 Month Changen/a
1 Year Changen/a
33 Year Changen/a
5 Year Changen/a
Change since IPO44.68%

Recent News & Updates

Recent updates

Shareholder Returns

SMMT *MX BiotechsMX Market
7D0%0%0%
1Yn/a0%0%

Return vs Industry: Insufficient data to determine how SMMT * performed against the MX Biotechs industry.

Return vs Market: Insufficient data to determine how SMMT * performed against the MX Market.

Price Volatility

Is SMMT *'s price volatile compared to industry and market?
SMMT * volatility
SMMT * Average Weekly Movementn/a
Biotechs Industry Average Movement0%
Market Average Movement0%
10% most volatile stocks in MX Market0%
10% least volatile stocks in MX Market0%

Stable Share Price: SMMT *'s share price has been volatile over the past 3 months compared to the MX market.

Volatility Over Time: Insufficient data to determine SMMT *'s volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2003105Bob Dugganwww.summittxinc.com

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company’s lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab.

Summit Therapeutics Inc. Fundamentals Summary

How do Summit Therapeutics's earnings and revenue compare to its market cap?
SMMT * fundamental statistics
Market capMex$308.47b
Earnings (TTM)-Mex$3.90b
Revenue (TTM)n/a

0.0x

P/S Ratio

-79.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SMMT * income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$196.68m
Earnings-US$196.68m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.27
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio5.6%

How did SMMT * perform over the long term?

See historical performance and comparison